Company intelligence / Profile preview
Akaza Biopharma
San Diego, California, United Statesakazabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Akaza Biopharma is a clinical-stage biotechnology company dedicated to the discovery and development of small molecule therapies for autoimmune and inflammatory diseases. The company's lead program, AKZ-001, is an oral, small molecule inhibitor of RORγt, a master regulator of the Th17 cell lineage and the production of IL-17. By targeting this pathway, Akaza aims to provide effective oral alternatives to injectable biologics for patients suffering from chronic conditions like psoriasis and inflammatory bowel disease. The company was founded by industry veterans and scientific leaders from the Scripps Research Institute and Calibr.
- Therapeutic areas
- ImmunologyDermatologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CalibrScripps Research Institute
Beyond the preview
Go deeper on Akaza Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akaza Biopharma.